TRCT
RNTX

Tower Research Capital (TRC)’s Rein Therapeutics RNTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.41K Buy
3,391
+1,434
+73% +$1.78K ﹤0.01% 4201
2025
Q4 		$2.27K Sell
1,957
-3,072
-61% -$4.23K ﹤0.01% 4564
2025
Q3 		$5.76K Buy
5,029
+2,098
+72% +$2.66K ﹤0.01% 4205
2025
Q2 		$4.1K Sell
2,931
-526
-15% -$947 ﹤0.01% 4380
2025
Q1 		$6.12K Buy
3,457
+877
+34% +$1.84K ﹤0.01% 4066
2024
Q4 		$5.93K Buy
2,580
+2,337
+962% +$7.08K ﹤0.01% 4224
2024
Q3 		$860 Sell
243
-3,621
-94% -$9.68K ﹤0.01% 5251
2024
Q2 		$10.7K Buy
3,864
+1,844
+91% +$7.58K ﹤0.01% 4127
2024
Q1 		$13.4K Sell
2,020
-206
-9% -$986 ﹤0.01% 3398
2023
Q4 		$6.79K Sell
2,226
-2,283
-51% -$4.45K ﹤0.01% 4697
2023
Q3 		$6.85K Buy
4,509
+767
+20% +$1.3K ﹤0.01% 4548
2023
Q2 		$6.7K Buy
3,742
+429
+13% +$661 ﹤0.01% 4672
2023
Q1 		$4K Buy
3,313
+909
+38% +$1.95K ﹤0.01% 5122
2022
Q4 		$5K Buy
+2,404
New +$8.08K ﹤0.01% 4931
2022
Q3 		– Sell
-1,685
Closed -$9K – 6575
2022
Q2 		$9K Buy
1,685
+1,188
+239% +$10.9K ﹤0.01% 4600
2022
Q1 		$5K Buy
497
+444
+838% +$4.02K ﹤0.01% 5127
2021
Q4 		$1K Buy
+53
New +$820 ﹤0.01% 5904
2021
Q3 		– Sell
-136
Closed -$3K – 6260
2021
Q2 		$3K Buy
+136
New +$3.39K ﹤0.01% 4970
2020
Q4 		– Sell
-203
Closed -$5K – 5461
2020
Q3 		$5K Buy
+203
New +$4.78K ﹤0.01% 4383
2019
Q1 		– Sell
-62
Closed -$1K – 4362
2018
Q4 		$1K Buy
62
+52
+520% +$2.09K ﹤0.01% 3686
2018
Q3 		$1K Buy
10
+7
+233% +$471 ﹤0.01% 3640
2018
Q2 		$0 Sell
3
-23
-88% -$2.6K ﹤0.01% 4133
2018
Q1 		$4K Sell
26
-14
-35% -$2.5K ﹤0.01% 2814
2017
Q4 		$8K Buy
+40
New +$9.59K ﹤0.01% 2692

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Tower Research Capital (TRC)'s RNTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Rein Therapeutics (RNTX) stake by 73% in Q1 2026, buying an estimated $1.78K and bringing the position to 3,391 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #4201.

Tower Research Capital (TRC) first reported a position in RNTX in Q4 2017 and has held it in 24 quarters since. The position peaked at $13.4K in Q1 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Tower Research Capital (TRC) held 3,391 shares of Rein Therapeutics worth $4.41K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,434 Rein Therapeutics shares in Q1 2026, an estimated $1.78K.
  • Rein Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4201 holding.
  • Tower Research Capital (TRC) first reported a position in Rein Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Rein Therapeutics position peaked at $13.4K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.